BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 21636254)

  • 1. Adherence to antipsychotic drug treatment in early-episode schizophrenia: a six-month naturalistic follow-up study.
    Baloush-Kleinman V; Levine SZ; Roe D; Shnitt D; Weizman A; Poyurovsky M
    Schizophr Res; 2011 Aug; 130(1-3):176-81. PubMed ID: 21636254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals.
    Day JC; Bentall RP; Roberts C; Randall F; Rogers A; Cattell D; Healy D; Rae P; Power C
    Arch Gen Psychiatry; 2005 Jul; 62(7):717-24. PubMed ID: 15997012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are we addressing the 'right stuff' to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication.
    Beck EM; Cavelti M; Kvrgic S; Kleim B; Vauth R
    Schizophr Res; 2011 Oct; 132(1):42-9. PubMed ID: 21820875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication adherence and subjective weight perception in patients with first-episode psychotic disorder.
    Wong MM; Chen EY; Lui SS; Tso S
    Clin Schizophr Relat Psychoses; 2011 Oct; 5(3):135-41. PubMed ID: 21983497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How do socio-demographic and clinical factors interact with adherence attitude profiles in schizophrenia? A cluster-analytical approach.
    Beck EM; Cavelti M; Wirtz M; Kossowsky J; Vauth R
    Psychiatry Res; 2011 May; 187(1-2):55-61. PubMed ID: 21074860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia.
    Yang J; Ko YH; Paik JW; Lee MS; Han C; Joe SH; Jung IK; Jung HG; Kim SH
    Schizophr Res; 2012 Feb; 134(2-3):226-31. PubMed ID: 22133906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug attitude and other predictors of medication adherence in schizophrenia: 12 months of electronic monitoring (MEMS(®)) in the Swedish COAST-study.
    Brain C; Allerby K; Sameby B; Quinlan P; Joas E; Karilampi U; Lindström E; Eberhard J; Burns T; Waern M
    Eur Neuropsychopharmacol; 2013 Dec; 23(12):1754-62. PubMed ID: 24091164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder.
    Byerly MJ; Nakonezny PA; Rush AJ
    Schizophr Res; 2008 Mar; 100(1-3):60-9. PubMed ID: 18255269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with antipsychotic medication adherence in community-based patients with schizophrenia in Hong Kong: a cross sectional study.
    Bressington D; Mui J; Gray R
    Int J Ment Health Nurs; 2013 Feb; 22(1):35-46. PubMed ID: 22738372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonadherence to antipsychotics: the role of positive attitudes towards positive symptoms.
    Moritz S; Hünsche A; Lincoln TM
    Eur Neuropsychopharmacol; 2014 Nov; 24(11):1745-52. PubMed ID: 25444234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence styles of schizophrenia patients identified by a latent class analysis of the Medication Adherence Rating Scale (MARS): a six-month follow-up study.
    Jaeger S; Pfiffner C; Weiser P; Kilian R; Becker T; Längle G; Eschweiler GW; Croissant D; Schepp W; Steinert T
    Psychiatry Res; 2012 Dec; 200(2-3):83-8. PubMed ID: 22534500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment adherence and insight in schizophrenia.
    Bitter I; Fehér L; Tényi T; Czobor P
    Psychiatr Hung; 2015; 30(1):18-26. PubMed ID: 25867885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative impact of self-stigmatization on attitude toward medication adherence in patients with psychosis.
    Uhlmann C; Kaehler J; Harris MS; Unser J; Arolt V; Lencer R
    J Psychiatr Pract; 2014 Sep; 20(5):405-10. PubMed ID: 25226204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of Antipsychotic Drugs for 24-Month Maintenance Treatment in First-Episode Schizophrenia: Evidence From a Community-Based "Real-World" Study.
    Zhang C; Chen MJ; Wu GJ; Wang ZW; Rao SZ; Zhang Y; Yi ZH; Yang WM; Gao KM; Song LS
    J Clin Psychiatry; 2016 Nov; 77(11):e1460-e1466. PubMed ID: 28076667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode.
    Perkins DO; Johnson JL; Hamer RM; Zipursky RB; Keefe RS; Centorrhino F; Green AI; Glick IB; Kahn RS; Sharma T; Tohen M; McEvoy JP; Weiden PJ; Lieberman JA;
    Schizophr Res; 2006 Mar; 83(1):53-63. PubMed ID: 16529910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Collaboration in outpatient antipsychotic drug treatment: analysis of potentially influencing factors.
    Klingberg S; Schneider S; Wittorf A; Buchkremer G; Wiedemann G
    Psychiatry Res; 2008 Nov; 161(2):225-34. PubMed ID: 18922582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited.
    Ascher-Svanum H; Weiden P; Nyhuis AW; Faries DE; Stauffer V; Kollack-Walker S; Kinon BJ
    Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):84-90, 90A. PubMed ID: 23446198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of perceived social support on medication adherence in first-episode psychosis.
    Rabinovitch M; Cassidy C; Schmitz N; Joober R; Malla A
    Can J Psychiatry; 2013 Jan; 58(1):59-65. PubMed ID: 23327758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compliance and schizophrenia: the predictive potential of insight into illness, symptoms, and side effects.
    Kao YC; Liu YP
    Compr Psychiatry; 2010; 51(6):557-65. PubMed ID: 20965300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.